CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%
CSPC Pharmaceutical Group reported a 27% increase in 9M revenue and a 101.5% rise in profit, driven by finished-drug sales and AstraZeneca licence income. Bulk products and functional food sales declined due to market pressures.
How this was made

The 30-second read
Why it matters
The earnings beat suggests stronger demand for finished‑drug products and successful licensing with AstraZeneca, offsetting declines in bulk and functional food segments.
Market read
First‑report earnings data with significant top‑line and profit growth, likely to move the stock and influence sector sentiment.
What to watch
Potential headwinds from price competition and procurement pressures on bulk products.
Background
CSPC Pharmaceutical Group is a leading Chinese pharma company listed in Hong Kong (1093.HK). The earnings release covers the first nine months of 2026.
Market effects
Highlights strength in China's pharmaceutical sector and potential for more licensing deals.
May boost sentiment toward Hong Kong‑listed pharma stocks.
Shows continued demand for licensed drug products from multinational partners.
Counterpoint
If the revenue growth is not sustainable, the stock could face a pull‑back after the initial rally.
Key entities
- companyCSPC Pharmaceutical Group Limited
Chinese pharmaceutical manufacturer (HK:1093.HK).
- partnerAstraZeneca
Provided licence income contributing to CSPC's earnings.

